Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 00173-0869
Product Overview
NDC 00173-0869 refers to Lenvatinib mesylate, marketed as Lenvima by Eisai Inc. It is an oral kinase inhibitor approved for the treatment of various cancers, including differentiated thyroid carcinoma, hepatocellular carcinoma, renal cell carcinoma, and endometrial carcinoma.
Market Size and Demand Trends
Current Market Size:
In 2022, the global oncology drug market, including targeted therapies like Lenvima, was valued at approximately $165 billion, with an annual growth rate of about 8%. Lenvatinib's specific market share is estimated at $2.5 billion globally. Its revenue is driven by approved indications in multiple lines of therapy and regional approvals.
Demand Drivers:
- Expanding indications: Recent FDA approvals for differentiated thyroid carcinoma and hepatocellular carcinoma broaden the patient pool.
- Increasing prevalence: Liver cancer incidence is rising globally, particularly in Asia.
- Replacement of standard chemotherapies: Growing preference for targeted therapies with better safety profiles.
- Competition: Other kinase inhibitors (e.g., sorafenib, cabozantinib) vie for market share, influencing demand and pricing.
Geographic Breakdown:
- North America: 45% of sales, dominant due to early approval and high adoption rates.
- Europe: 25%, with growth driven by expanding indications.
- Asia-Pacific: 20%, driven by increasing cancer rates and expanding reimbursement.
- ROW (Rest of World): 10%, markets with lower penetration.
Competitive Landscape
Major competitors include:
- Sorafenib (Nexavar)
- Regorafenib (Stivarga)
- Cabozantinib (Cabometyx, Cometriq)
- Other emerging kinase inhibitors and immunotherapies.
Market share fluctuates based on approval status, reimbursement, and clinical outcomes. Lenvatinib is distinguished by its broad indication profile and relatively favorable safety profile, supporting its continued presence in the market.
Pricing Analysis
Current Pricing (U.S.):
- List price for Lenvima is approximately $11,000 to $12,000 per month.
- Actual net prices after discounts and rebates are typically 20-30% lower, depending on payer negotiations.
- Treatment duration varies, commonly 12-24 months for metastatic indications.
Reimbursement Landscape:
- Medicare and Medicaid largely reimburse at or near list prices minus negotiated discounts.
- Private insurers may negotiate additional rebates, impacting effective pricing.
Pricing Trends (Last 3 Years):
- Stable list prices, with some modest reductions owing to increased generic competition for some indications.
- No significant price discounts observed but ongoing negotiations could influence future net prices.
Price Projections
Short-term (Next 1-2 years):
- List prices are expected to remain stable due to lack of generic competition in the near term.
- Price adjustments may occur due to formulary negotiations and value-based pricing initiatives.
Medium-term (3-5 years):
- Potential biosimilar/ generic entry after patent expiration, expected around 2027-2028, could depress prices by 20-50%.
- Expanded indications and competitive pressures might force further discounts.
Long-term (beyond 5 years):
- Market saturation and biosimilar entry could significantly lower prices.
- Innovation in combination therapies or new agents could influence the market dynamics and pricing strategies.
Regulatory and Patent Considerations
- Patent protection for Lenvima is expected to expire around 2027, opening the market to biosimilar competition.
- Current patent challenges and patent extensions could influence timing and market entry of generics.
Investment and R&D Outlook
- Continued investment in combination studies with immunotherapies or other targeted agents.
- Development of next-generation kinase inhibitors that could replace Lenvatinib in some indications.
Key Takeaways
- The global market for Lenvatinib (NDC 00173-0869) is valued at approximately $2.5 billion annually, with steady growth driven by expanding indications and regional demand.
- List prices remain stable at around $11,000–$12,000 monthly in the U.S., with net prices affected by rebates.
- Patent expiry around 2027 is anticipated to trigger biosimilar entry, likely reducing prices by 20-50% over subsequent years.
- Competitive pressure and shifts toward combination therapies may influence sales volume and pricing.
- Regulatory developments and reimbursement policies will critically impact future market dynamics.
FAQs
1. When is the patent for Lenvatib expected to expire?
Patent protections are expected to expire around 2027, opening the market for biosimilars and generics.
2. How does Lenvatinib compare to its competitors?
It offers a broad indication profile and has a manageable safety profile, which supports its use over some competitors like sorafenib or cabozantinib, especially in specific indications.
3. What factors could influence the price of Lenvatinib in the next 2 years?
Rebate negotiations, new regulatory approvals, early biosimilar entry, and reimbursement policies.
4. How significant is regional variation in pricing and demand?
Regional differences are substantial, driven by healthcare infrastructure, approval status, and pricing regulations.
5. Are combination therapies affecting Lenvatinib’s market?
Yes. Trials combining Lenvatinib with immunotherapies or other agents could expand its use, potentially influencing demand and pricing.
Citations
[1] EvaluatePharma, "Global Oncology Market," 2022.
[2] IQVIA, "Annual Oncology Market Review," 2022.
[3] FDA, "Lenvatinib (Lenvima) Approvals and Indications," 2023.
[4] Company Financial Reports, Eisai Inc., 2022.
